FDA approves Novo Nordisk fast-acting insulin Fiasp
The U.S. Food and Drug Administration (FDA) on Friday approved Novo Nordisk's fast-acting insulin to treat diabetes.
The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. It is already approved in Canada and Europe.
Fiasp, or faster-acting insulin asparte, is designed to work faster than existing fast-acting insulin such as Eli Lilly and Co's Humalog and Novo Nordisk's own NovoLog, known as NovoRapid outside the United States.
Last year the FDA declined to approve the product and requested additional information.
(Reporting by Toni Clarke in Washington; Editing by Chizu Nomiyama)
Approvesblood sugardiabetesEli Lillyfast-acting insulinFDAFiaspHumaloginsulinNovo NordiskNovoLogNovoRapidpharma news
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd